Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ASPH | Q12797 | 2/20 | 0.39 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | KMO | O15229 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1350020 | 0.81 | ATR (0.34) | KDM4EASPHKDM8ATRLMNA | |
| SCHEMBL238763 | 0.78 | SMN1; SMN2 (0.46) | KDM4ELMNASMN1; SMN2POLBTDP1 | |
| SCHEMBL6705128 | 0.77 | ATR (0.32) | ATRLMNASMN1; SMN2POLBTDP1 | |
| SCHEMBL25396869 | 0.76 | NOTUM (0.38) | KMO | |
| SCHEMBL1699332 | 0.75 | ATR (0.36) | KDM4EASPHKDM8ATRLMNA | |
| SCHEMBL28906545 | 0.75 | SMN1; SMN2 (0.41) | KDM4ELMNASMN1; SMN2POLB | |
| SCHEMBL14909869 | 0.73 | PIK3CA (0.40) | KDM4EASPHKDM8LMNASMN1; SMN2 | |
| SCHEMBL16776759 | 0.73 | GCK (0.39) | — | |
| SCHEMBL31352713 | 0.72 | SSTR4 (0.41) | KDM4EGPBAR1ATRLMNASMN1; SMN2 | |
| SCHEMBL28906476 | 0.72 | KEAP1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737450-A1 | HETEROAROMATIC FORMAMIDE COMPOUNDS AND USES THEREOF IN MEDICINE | Longwood Pharmaceuticals (Hangzhou) Co., Ltd (CN) | 2026-05-06 | — | — | EP | disclosed |
| WO-2023098425-A1 | KRAS INHIBITORS, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 上海和誉生物医药科技有限公司 | 2023-06-08 | — | — | WO | disclosed |
| WO-2023098426-A1 | 7-(NAPHTHALENE-L-YL)PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海和誉生物医药科技有限公司 | 2023-06-08 | — | — | WO | disclosed |
| WO-2022161489-A1 | PENTAHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海艾力斯医药科技股份有限公司 | 2022-08-04 | — | — | WO | disclosed |
| EP-2589592-B1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM CORP (JP) | 2018-08-22 | — | — | EP | disclosed |
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8772320-B2 | — | — | 2014-07-08 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| EP-2589592-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM Corporation (JP) | 2013-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, CD38, BTK | KDM4E 2420/4885ASPH 2422/4885KDM8 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.